🚀 VC round data is live in beta, check it out!
Biogena Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biogena and similar public comparables like New Nordic Healthbrands, Willamette Valley, Ecomiam, Industrias Productos Alimenticios and more.
Biogena Overview
About Biogena
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
Founded
2020
HQ
Employees
3
Website
Sectors
Financials (FY)
EV
$14M
Biogena Financials
Biogena reported last fiscal year revenue of $412K and EBITDA of $349K.
In the same fiscal year, Biogena generated $349K in EBITDA and $344K in net income.
Biogena P&L
In the most recent fiscal year, Biogena reported revenue of $412K and EBITDA of $349K.
Biogena expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $412K | XXX | XXX | XXX |
| EBITDA | — | XXX | $349K | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 85% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 51% | XXX | XXX | XXX |
| Net Profit | — | XXX | $344K | XXX | XXX | XXX |
| Net Margin | — | XXX | 84% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biogena Stock Performance
Biogena has current market cap of $14M, and enterprise value of $14M.
Market Cap Evolution
Biogena's stock price is $3.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14M | $14M | -1.0% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiogena Valuation Multiples
Biogena trades at 33.1x EV/Revenue multiple, and 39.2x EV/EBITDA.
Biogena Financial Valuation Multiples
As of April 21, 2026, Biogena has market cap of $14M and EV of $14M.
Equity research analysts estimate Biogena's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biogena has a P/E ratio of 39.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14M | XXX | $14M | XXX | XXX | XXX |
| EV (current) | $14M | XXX | $14M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 33.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 39.2x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 64.9x | XXX | XXX | XXX |
| P/E | — | XXX | 39.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biogena Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biogena Margins & Growth Rates
Biogena's revenue in the last fiscal year grew by 0%.
Biogena's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Biogena's rule of 40 is 84% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biogena's rule of X is 84% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Biogena Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 85% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (6%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 84% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 84% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biogena Public Comps
See public comps and valuation multiples for other Food & Beverages comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biogena | XXX | XXX | XXX | XXX | XXX | XXX |
| New Nordic Healthbrands | XXX | XXX | XXX | XXX | XXX | XXX |
| Willamette Valley | XXX | XXX | XXX | XXX | XXX | XXX |
| Ecomiam | XXX | XXX | XXX | XXX | XXX | XXX |
| Industrias Productos Alimenticios | XXX | XXX | XXX | XXX | XXX | XXX |
| Fountain | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biogena M&A Activity
Biogena acquired XXX companies to date.
Last acquisition by Biogena was on XXXXXXXX, XXXXX. Biogena acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biogena
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiogena Investment Activity
Biogena invested in XXX companies to date.
Biogena made its latest investment on XXXXXXXX, XXXXX. Biogena invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biogena
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biogena
| When was Biogena founded? | Biogena was founded in 2020. |
| Where is Biogena headquartered? | Biogena is headquartered in Austria. |
| How many employees does Biogena have? | As of today, Biogena has over 3 employees. |
| Is Biogena publicly listed? | Yes, Biogena is a public company listed on Wiener Börse. |
| What is the stock symbol of Biogena? | Biogena trades under BIO ticker. |
| When did Biogena go public? | Biogena went public in 2020. |
| Who are competitors of Biogena? | Biogena main competitors are New Nordic Healthbrands, Willamette Valley, Ecomiam, Industrias Productos Alimenticios. |
| What is the current market cap of Biogena? | Biogena's current market cap is $14M. |
| What is the current revenue of Biogena? | Biogena's last fiscal year revenue is $412K. |
| What is the current EV/Revenue multiple of Biogena? | Current revenue multiple of Biogena is 33.1x. |
| Is Biogena profitable? | No, Biogena is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.